Trial 4B-15-12


A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) versus Observation as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Immunotherapy
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  David Quinn, M.D.
Other Trial Staff:  Cheryl Kefauver, Coordinator, Lagrimas Ilagan, D.M., Roberto Tejada, D.M., Taison Tran, Coordinator, Elysse Faye Ballon, Coordinator, Sarmad Sadeghi, D.M., Charis Barg, Coordinator, Bartolo Santos, Coordinator, Kristy Watkins, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.